Three certificates issued by Bureau Veritas support application in SOLAS-regulated marine environments across global, EU-flagged, and UK-flagged vessels.MINNETONKA, Minn., June 9, 2026 /PRNewswire/ --...
OSLO, Norway, June 8, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, and Artera, a leading precision medicine company, announce launch...
Vancouver, Canada, June 08, 2026 (GLOBE NEWSWIRE) --
No deposit bonus casinos are receiving more attention in 2026 as players look for ways to try an online casino before spending their own money. Offers such as 50 no deposit free spins and $200 no deposit bonus 200 free spins real money allow users to test games, review bonus terms, and understand how a casino works before deciding whether to make a deposit.
The collaboration builds the first digital twin of a stellarator fusion power plant and leverages world leading AI, physics, and engineering for the U.S. Department of Energy’s Genesis Mission
New Facility, Open July 1st, Supports Continued Growth and Reflects Market Shift Toward Centralized Execution, and Lifecycle-Driven Service Supply chainsPARSIPPANY, N.J., June 8, 2026...
TAIPEI, June 8, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that Foresee's oral ALDH2 activator, mirivadelgat, has been selected to enter clinical testing in...
SAN DIEGO, June 8, 2026 /PRNewswire/ -- Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for...
Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6
Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM’s differentiated approach and high performance